Global Blood Therapeutics
181 Oyster Point Blvd
South San Francisco
California
94080
United States
Website: http://www.gbt.com/
Email: info@gbt.com
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
278 articles with Global Blood Therapeutics
-
Bay Area Biotech Companies Hiring Now
10/19/2022
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here's a look at a few of the bay area biotech companies hiring now. -
Pfizer Completes Acquisition of Global Blood Therapeutics
10/5/2022
Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Global Blood Therapeutics, Inc.
-
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
9/15/2022
Global Blood Therapeutics, Inc. announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell disease treatment, research and education.
-
GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference
9/8/2022
Global Blood Therapeutics, Inc. and the Sickle Cell Disease Association of America, Inc. will host the 11th Annual Sickle Cell Disease Therapeutics Conference on Wednesday, September 14th.
-
In the second half of the calendar year, the biopharma industry continues to ascend in mergers and acquisitions, new drug approvals and big investments, indicate market confidence and growth.
-
Pfizer announced Monday that it is acquiring the hematology-focused company for $5.4 billion in order to bolster its presence in the multi-billion dollar rare disease market.
-
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
8/8/2022
Pfizer Inc. and Global Blood Therapeutics, Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease.
-
Shares of Global Blood Therapeutics are surging once again after reports indicate Pfizer is the mystery suitor for the company. Pfizer could potentially pay as much as $5 billion for the company.
-
GBT Announces New Employment Inducement Grants - Aug 04, 2022
8/4/2022
Global Blood Therapeutics, Inc. announced that on August 1, 2022, the compensation committee of GBT’s board of directors granted 10 new employees restricted stock units for an aggregate of 30,450 shares of the company’s common stock.
-
GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
7/29/2022
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after U.S. financial markets close.
-
MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
7/26/2022
Global Blood Therapeutics, Inc. announced that the Medicines and Healthcare products Regulatory Agency has granted Great Britain marketing authorization for Oxbryta® for the treatment of hemolytic anemia due to sickle cell disease in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
-
GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
7/14/2022
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an expanded access program (EAP) for voxelotor in Brazil for the treatment of sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older who cannot satisfactorily be treated with a medicine authorized for use in Brazil.
-
GBT Announces New Employment Inducement Grants - July 07, 2022
7/7/2022
Global Blood Therapeutics, Inc. announced that on July 1, 2022, the compensation committee of GBT’s board of directors granted 22 new employees options to purchase an aggregate of 10,600 shares of the company’s common stock with a per share exercise price of $32.80 and restricted stock units for an aggregate 76,600 shares of the company’s common stock.
-
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell DiseasePhase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trial
6/29/2022
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial of GBT021601 (GBT601), the company’s investigational next-generation sickle hemoglobin (HbS) polymerization inhibitor.
-
New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease
6/13/2022
Global Blood Therapeutics, Inc. announced results from the Sickle Cell Health Awareness, Perspectives and Experiences survey, a multinational survey on the burden of sickle cell disease and unmet needs as reported by more than 1,300 patients, caregivers and healthcare professionals in 10 countries.
-
GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
6/10/2022
Global Blood Therapeutics, Inc. announced new data from a large multicenter real-world evidence study supporting the clinical use of Oxbryta® for the treatment of sickle cell disease in patients 12 years of age and older.
-
GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease
6/6/2022
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted both orphan drug and rare pediatric disease designations for inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease (SCD).
-
GBT Announces New Employment Inducement Grants - June 02, 2022
6/2/2022
Global Blood Therapeutics, Inc. announced that on June 1, 2022, the compensation committee of GBT’s board of directors granted 10 new employees restricted stock units for an aggregate of 33,700 shares of the company’s common stock.
-
GBT to Host Investor Conference Call on Friday, June 10 and Participate in Upcoming Investor Conferences
6/1/2022
Global Blood Therapeutics, Inc. announced that it will host a conference call and webcast for the investment community on Friday, June 10, 2022, at 3:00 p.m. CEST to discuss data on its sickle cell programs presented at the European Hematology Association Annual Congress and to provide business and R&D updates.
-
GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress
5/12/2022
Global Blood Therapeutics, Inc. announced five abstracts related to its sickle cell disease programs will be presented at the European Hematology Association 2022 Hybrid Congress.